TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Radial Artery Access With Ultrasound Trial
Brief Summary: Radial artery access for cardiac catheterization can require multiple attempts. Multiple attempts increase the time required, patient discomfort, and the risk of arterial spasm. Ultrasound guidance has been shown in other studies to reduce the number of attempts and complications in central venous and femoral artery access. This study will test if the addition of ultrasound guidance reduces the number of attempts and time required to access the radial artery.


Options:
A: Arm Label: Dynamic needle tip positioning; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Dynamic needle tip positioning under ultrasound-guidance | Arm Label: Conventional long-axis; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional long-axis view | Intervention Type: PROCEDURE; Name: Dynamic needle tip positioning under ultrasound-guidance; Assigned to Arm(s): Dynamic needle tip positioning | Intervention Type: PROCEDURE; Name: Conventional long-axis view; Assigned to Arm(s): Conventional long-axis
B: Arm Label: Palpation only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RAP palpation only | Arm Label: Ultrasound guidance; Type: EXPERIMENTAL; Interventions: Procedure: RAP with ultrasound guidance | Intervention Type: PROCEDURE; Name: RAP palpation only; Assigned to Arm(s): Palpation only | Intervention Type: PROCEDURE; Name: RAP with ultrasound guidance; Assigned to Arm(s): Ultrasound guidance
C: Arm Label: Ultrasound group; Type: EXPERIMENTAL; Interventions: Procedure: Ultrasound -guided cannulation | Arm Label: Palpation group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Palpation -guided cannulation | Intervention Type: PROCEDURE; Name: Ultrasound -guided cannulation; Assigned to Arm(s): Ultrasound group | Intervention Type: PROCEDURE; Name: Palpation -guided cannulation; Assigned to Arm(s): Palpation group
D: Arm Label: Palpation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Palpation | Arm Label: Ultrasound; Type: EXPERIMENTAL; Interventions: Procedure: Ultrasound guidance | Intervention Type: PROCEDURE; Name: Ultrasound guidance; Assigned to Arm(s): Ultrasound | Intervention Type: PROCEDURE; Name: Palpation; Assigned to Arm(s): Palpation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Radial Artery Access With Ultrasound Trial
Brief Summary: Radial artery access for cardiac catheterization can require multiple attempts. Multiple attempts increase the time required, patient discomfort, and the risk of arterial spasm. Ultrasound guidance has been shown in other studies to reduce the number of attempts and complications in central venous and femoral artery access. This study will test if the addition of ultrasound guidance reduces the number of attempts and time required to access the radial artery.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Ultrasound; Type: EXPERIMENTAL; Interventions: Device: Real-time Ultrasound Guidance (Site-Rite 5 or 6 machine) | Intervention Type: DEVICE; Name: Real-time Ultrasound Guidance (Site-Rite 5 or 6 machine); Assigned to Arm(s): Ultrasound
B: Arm Label: Dynamic; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: dynamic | Arm Label: Regular-triangle; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Regular-triangle | Intervention Type: BEHAVIORAL; Name: dynamic; Assigned to Arm(s): Dynamic | Intervention Type: BEHAVIORAL; Name: Regular-triangle; Assigned to Arm(s): Regular-triangle
C: Arm Label: Palpation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Palpation | Arm Label: Ultrasound; Type: EXPERIMENTAL; Interventions: Procedure: Ultrasound guidance | Intervention Type: PROCEDURE; Name: Ultrasound guidance; Assigned to Arm(s): Ultrasound | Intervention Type: PROCEDURE; Name: Palpation; Assigned to Arm(s): Palpation
D: Arm Label: Arterial catheter; Type: OTHER; Interventions: Procedure: Laying a radial or femoral arterial catheter | Arm Label: Placement; Type: OTHER; Interventions: Procedure: Laying a radial or femoral arterial catheter | Intervention Type: PROCEDURE; Name: Laying a radial or femoral arterial catheter; Assigned to Arm(s): Arterial catheter, Placement

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Radial Artery Access With Ultrasound Trial
Brief Summary: Radial artery access for cardiac catheterization can require multiple attempts. Multiple attempts increase the time required, patient discomfort, and the risk of arterial spasm. Ultrasound guidance has been shown in other studies to reduce the number of attempts and complications in central venous and femoral artery access. This study will test if the addition of ultrasound guidance reduces the number of attempts and time required to access the radial artery.


Options:
A: Arm Label: Palpation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Palpation | Arm Label: Ultrasound; Type: EXPERIMENTAL; Interventions: Procedure: Ultrasound guidance | Intervention Type: PROCEDURE; Name: Ultrasound guidance; Assigned to Arm(s): Ultrasound | Intervention Type: PROCEDURE; Name: Palpation; Assigned to Arm(s): Palpation
B: Arm Label: Distal radial artery access; Type: EXPERIMENTAL; Interventions: Procedure: Distal radial artery access | Arm Label: Proximal radial artery access; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Proximal radial artery surgery | Intervention Type: PROCEDURE; Name: Distal radial artery access; Assigned to Arm(s): Distal radial artery access | Intervention Type: PROCEDURE; Name: Proximal radial artery surgery; Assigned to Arm(s): Proximal radial artery access
C: Arm Label: Fluoroscopic + Ultrasound Guidance; Type: EXPERIMENTAL; Interventions: Procedure: Fluoroscopic + Ultrasound Guidance | Arm Label: Fluoroscopic Guidance Alone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Fluoroscopic + Ultrasound Guidance; Assigned to Arm(s): Fluoroscopic + Ultrasound Guidance
D: Arm Label: Infant; Type: EXPERIMENTAL; Interventions: Other: Long-axis/in-plane US-guided arterial catheterization, Other: Short-axis/out-of-plane US-guided arterial catheterization | Arm Label: Preschool child; Type: EXPERIMENTAL; Interventions: Other: Long-axis/in-plane US-guided arterial catheterization, Other: Short-axis/out-of-plane US-guided arterial catheterization | Intervention Type: OTHER; Name: Long-axis/in-plane US-guided arterial catheterization; Assigned to Arm(s): Infant, Preschool child | Intervention Type: OTHER; Name: Short-axis/out-of-plane US-guided arterial catheterization; Assigned to Arm(s): Infant, Preschool child

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Brief Summary: The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.


Options:
A: Arm Label: TAS-102; Type: EXPERIMENTAL; Interventions: Drug: TAS-102 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TAS-102; Assigned to Arm(s): TAS-102 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo/FOLFIRI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Arm Label: Aflibercept/FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Aflibercept/FOLFIRI
C: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy, Drug: Bevacizumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CPT-11 and TS-1 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: CPT-11, 5-FU and l-LV | Intervention Type: DRUG; Name: CPT-11 and TS-1; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CPT-11, 5-FU and l-LV; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Brief Summary: The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.


Options:
A: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy, Drug: Bevacizumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab
B: Arm Label: Panitumumab plus best supportive care; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Arm Label: Best Supportive Care; Type: OTHER; Interventions: Other: Best supportive care | Intervention Type: OTHER; Name: Best supportive care; Assigned to Arm(s): Best Supportive Care | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab plus best supportive care
C: Arm Label: FOLFIRI + Ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab, Drug: Irinotecan, Drug: Folinic Acid, Drug: 5-Fluorouracil | Arm Label: FOLFIRI + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Irinotecan, Drug: Folinic Acid, Drug: 5-Fluorouracil | Intervention Type: BIOLOGICAL; Name: Ramucirumab; Assigned to Arm(s): FOLFIRI + Ramucirumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): FOLFIRI + Placebo | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab | Intervention Type: DRUG; Name: Folinic Acid; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab
D: Arm Label: TAS-102; Type: EXPERIMENTAL; Interventions: Drug: TAS-102 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TAS-102; Assigned to Arm(s): TAS-102 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravenous Lidocaine for Effective Pain Relief After Thyroidectomy: a Prospective, Randomized, Double-blind, Placebo-controlled Study
Brief Summary: This prospective randomized study aims to evaluate the effectiveness of intravenous lidocaine injection on the relief of pain in patients undergoing thyroidectomy.

A total 56 patients will be randomized into one of two groups(group C or group I) based on Excel number generation.

Patients in group C will receive normal saline intravenous injection, and patients in group I will receive an intravenous bolus injection of 1.5mg/kg lidocaine followed by a continuous lidocaine infusion of 2mg/kg/hr.

Visual analogue scale pain scores, fentanyl consumption, the frequency at which patients pushed the button(FPB) of a patient-controlled analgesia system, and presence or absence of nausea and vomiting will be recorded at 2,4,8,12,24,48 hours postoperatively.


Options:
A: Arm Label: Intravenous lidocaine injection group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous lidocaine injection | Arm Label: Intraperitoneal lidocaine irrigation group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intraperitoneal lidocaine irrigation group | Arm Label: Intravenous normal saline group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Intravenous normal saline injection | Intervention Type: DRUG; Name: Intravenous lidocaine injection; Assigned to Arm(s): Intravenous lidocaine injection group | Intervention Type: DRUG; Name: Intraperitoneal lidocaine irrigation group; Assigned to Arm(s): Intraperitoneal lidocaine irrigation group | Intervention Type: DRUG; Name: Intravenous normal saline injection; Assigned to Arm(s): Intravenous normal saline group
B: Arm Label: The effect of perioperative lidocaine infusion; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Arm Label: The effect of perioperative magnesium infusion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): The effect of perioperative lidocaine infusion | Intervention Type: DRUG; Name: Magnesium; Assigned to Arm(s): The effect of perioperative magnesium infusion
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lidocaine; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Lidocaine
D: Arm Label: Intravenous lidocaine injection group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous lidocaine injection | Arm Label: Placebo control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Intravenous normal saline injection | Intervention Type: DRUG; Name: Intravenous lidocaine injection; Assigned to Arm(s): Intravenous lidocaine injection group | Intervention Type: DRUG; Name: Intravenous normal saline injection; Assigned to Arm(s): Placebo control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Intravenous Lidocaine and Intraperitoneal Lidocaine Irrigation for Effective Pain Relief After Laparoscopic Cholecystectomy: A Prospective, Randomized, Double-blind, Placebo-controlled Study
Brief Summary: This prospective randomized study aims to comparison the effectiveness of intravenous lidocaine injection and intraperitoneam lidocaine irrigation on the relief of pain in patients undergoing laparoscopic cholecystectomy.

A total of 83 patients will be randomized into one of three groups (group C or group I or group P) based on Excel number generation.

Patients in group C will receive normal saline intravenous injection, and patients in group I will receive an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.

Patients in group P will receive intraperitoneal lidocaine irrigation with 3.5 mg/kg lidocaine and normal saline 100cc.

Visual analogue scale pain scores, fentanyl consumption and the frequency at which patients pushed the button (FPB) of a patient-controlled analgesia system will be recorded at 2, 4, 8, 12, 24, 48 hours postoperatively.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: lidocaine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lidocaine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lidocaine; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Lidocaine
C: Arm Label: Intravenous lidocaine injection group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous lidocaine injection | Arm Label: Intraperitoneal lidocaine irrigation group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intraperitoneal lidocaine irrigation group | Arm Label: Intravenous normal saline group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Intravenous normal saline injection | Intervention Type: DRUG; Name: Intravenous lidocaine injection; Assigned to Arm(s): Intravenous lidocaine injection group | Intervention Type: DRUG; Name: Intraperitoneal lidocaine irrigation group; Assigned to Arm(s): Intraperitoneal lidocaine irrigation group | Intervention Type: DRUG; Name: Intravenous normal saline injection; Assigned to Arm(s): Intravenous normal saline group
D: Arm Label: Lidocaine; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Lidocaine | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study
Brief Summary: Multicenter, randomized, assessor-blinded controlled study of safety and effectiveness of the PneumRx, Inc. RePneu Lung Volume Reduction Coil (RePneu LVRC) System


Options:
A: Arm Label: RePneu Lung Volume Reduction Coil System; Type: EXPERIMENTAL; Interventions: Device: RePneu Lung Volume Reduction Coil System | Arm Label: Control arm is standard medical care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: RePneu Lung Volume Reduction Coil System; Assigned to Arm(s): RePneu Lung Volume Reduction Coil System
B: Arm Label: Lung Volume Reduction Coil (LVRC); Type: EXPERIMENTAL; Interventions: Device: Lung Volume Reduction Coil (LVRC) (PneumRx's) | Intervention Type: DEVICE; Name: Lung Volume Reduction Coil (LVRC) (PneumRx's); Assigned to Arm(s): Lung Volume Reduction Coil (LVRC)
C: Intervention Type: PROCEDURE; Name: Emphasys Endobronchial Valve and procedure; Assigned to Arm(s): N/A
D: Arm Label: PLVR; Type: EXPERIMENTAL; Interventions: Device: Polymeric Lung Volume Reduction System (PLVR) | Intervention Type: DEVICE; Name: Polymeric Lung Volume Reduction System (PLVR); Assigned to Arm(s): PLVR

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neoadjuvant Combination Biotherapy With Ipilimumab (3 mg/kg or 10 mg/kg) and High Dose IFN-Α2B in Patients With Locally/Regionally Advanced/Recurrent Melanoma: a Randomized Safety, Efficacy and Biomarker Study
Brief Summary: The purpose of this study is to evaluate the safety and potential effectiveness of a new treatment for advanced and recurrent melanoma involving the combination of Ipilimumab and IFN-α2b before surgery and to test for biomarker studies in blood and/or tumor to better understand this disease, how best to treat it and what patients should be treated with this combination.


Options:
A: Arm Label: Ipilimumab 10 mg/kg + HDI; Type: EXPERIMENTAL; Interventions: Drug: administration of ipilimumab10mg/kg | Arm Label: Ipilimumab 3mg/kg + HDI; Type: EXPERIMENTAL; Interventions: Drug: administration of ipilimumab 3mg/kg + HDI | Intervention Type: DRUG; Name: administration of ipilimumab10mg/kg; Assigned to Arm(s): Ipilimumab 10 mg/kg + HDI | Intervention Type: DRUG; Name: administration of ipilimumab 3mg/kg + HDI; Assigned to Arm(s): Ipilimumab 3mg/kg + HDI
B: Arm Label: Dabrafenib and Trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib and Trametinib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib and Trametinib
C: Arm Label: Dabrafenib plus Trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Arm Label: Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vemurafenib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib plus Trametinib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib plus Trametinib
D: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: pembrolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: pembrolizumab; Assigned to Arm(s): Pembrolizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Role of Epidermal Growth Factor Receptor (EGFR) Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib
Brief Summary: The purpose of this study is to investigate the influence of epidermal growth factor receptor mutations on the efficacy of erlotinib and gemcitabine in metastatic pancreatic cancer.


Options:
A: Arm Label: Gemcitabine; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Gemcitabine plus erlotinib; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Gemcitabine plus erlotinib
B: Arm Label: Folfirinox; Type: EXPERIMENTAL; Interventions: Drug: fluorouracil, Drug: irinotecan hydrochloride, Drug: leucovorin calcium, Drug: oxaliplatin | Arm Label: Gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine hydrochloride | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Folfirinox | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): Gemcitabine | Intervention Type: DRUG; Name: irinotecan hydrochloride; Assigned to Arm(s): Folfirinox | Intervention Type: DRUG; Name: leucovorin calcium; Assigned to Arm(s): Folfirinox | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): Folfirinox
C: Arm Label: Simtuzumab (open-label); Type: EXPERIMENTAL; Interventions: Drug: Simtuzumab, Drug: Gemcitabine | Arm Label: Simtuzumab 200 mg (randomized); Type: EXPERIMENTAL; Interventions: Drug: Simtuzumab, Drug: Gemcitabine | Arm Label: Simtuzumab 700 mg (randomized); Type: EXPERIMENTAL; Interventions: Drug: Simtuzumab, Drug: Gemcitabine | Arm Label: Placebo (randomized); Type: PLACEBO_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: Placebo to match simtuzumab | Intervention Type: DRUG; Name: Simtuzumab; Assigned to Arm(s): Simtuzumab (open-label), Simtuzumab 200 mg (randomized), Simtuzumab 700 mg (randomized) | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Placebo (randomized), Simtuzumab (open-label), Simtuzumab 200 mg (randomized), Simtuzumab 700 mg (randomized) | Intervention Type: DRUG; Name: Placebo to match simtuzumab; Assigned to Arm(s): Placebo (randomized)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine plus TS-1 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: TS-1 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine | Intervention Type: DRUG; Name: Gemcitabine plus TS-1; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: TS-1; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): 3

Answer: A